This study, although preclinical, provides several insights into the phenotypic plasticity of trametinib-resistant melanoma cells that might be considered in future clinical studies to enable the development of more personalized treatment for patients with melanoma resistant to BRAFV600/MEK inhibitors. Here, MAP2K7 is linked to melanoma.